CD8A and cancer: We also demonstrated that many other variables including age, sex, biopsy type, and most prior cancer therapies (excluding hormone-related and ICD-chemotherapy) do not strongly contribute to the baseline heterogeneity of Treg or proliferating CD8 T-cell levels, and therefore do not need to be controlled for either by design or in statistical analyses of clinical data.